Methods of treating pain by inhibition of VGF activity

Abstract

The present disclosure relates to a method of treating pain, in particular neuropathic pain, comprising administering a therapeutically effective amount of an inhibitor of VGF activity resulting from binding of VGF or a peptide of the type TLQP-21 to the receptor qC1qR. The disclosure also relates to and methods of screening for said inhibitors.

Claims

1. A method of treating neuropathic pain, comprising administering a therapeutically effective amount of an inhibitor of VGF activity resulting from binding of VGF or a TLQP-21 peptide to a gC1qR receptor, wherein TLQP-21 peptide comprises a peptide having the amino acid sequence set forth in SEQ ID NO:3, wherein the inhibitor is specific to VGF, the TLQP-21 peptide, or gC1qR, and wherein the inhibitor is an antibody or a binding fragment thereof.

2. The method of claim 1, wherein the neuropathic pain comprises neuropathic pain associated with nerve injury or damage, posttherapeutic neuropathy, HIV/AIDS, diabetic neuropathy, fibromyalgia, alcohol neuropathy, amputation, facial nerve problems, wherein the facial nerve problems comprise Bell's Palsy, cancer, multiple sclerosis, compression of a nerve by a tumor, diabetes, stroke or excessive inflammatory responses that result in tissue damage.

3. The method of claim 1, wherein the inhibitor blocks binding of VGF or the TLQP-21 peptide to the receptor gC1qR, wherein the TLQP-21 peptide comprises a peptide having the amino acid sequence set forth in SEQ ID NO:3.

4. The method of claim 1, wherein the inhibitor blocks signalling subsequent to binding of VGF or the TLQP-21 peptide to the receptor gC1qR, wherein the TLQP-21 peptide comprises a peptide having the amino acid sequence set forth in SEQ ID NO:3.

5. The method of claim 1, wherein the antibody is specific to VGF and an activity thereof associated with binding to gC1qR.

6. The method of claim 1, wherein the antibody is specific for the receptor gC1qR and the activity thereof associated with binding VGF or the TLQP-21 peptide, wherein the TLQP-21 peptide comprises a peptide having the amino acid sequence set forth in SEQ ID NO:3.

7. The method of claim 1, wherein the neuropathic pain is nociceptive pain.

8. The method of claim 1, wherein the neuropathic pain is allodynia.

9. The method of claim 1, wherein the neuropathic pain is continuous.

10. The method of claim 1, wherein the neuropathic pain is episodic.

11. The method of claim 1, wherein the neuropathic pain is peripheral.

12. The method of claim 1, wherein the neuropathic pain is central.

Description

BRIEF DESCRIPTION OF THE FIGURES

(1) FIG. 1 Shows typical immunofluorescence images showing the presence of VGF peptide (light) in lumbar DRG neurons ipsilateral to A) VZV infection and B) L5 SNT, but not in C) uninfected fibroblast-injected control, nor D) sham-operated animals fourteen days after injury. Scale bar 100 μm. VGF-like immunoreactivity is increased in small diameter DRG neurons following varicella zoster infection and L5 spinal nerve transection.

(2) FIG. 2 Shows 100 nM TLQP-21 (A) but not scrambled TLQP-21 (B) elicits an increase in intracellular Ca2+ levels in cultured macrophages.

(3) FIG. 2A TLQP-21 elicits intracellular Ca2+ increase in macrophages and microglia. a, Applying 100 nM TLQP-21 to cultured bone marrow-derived macrophages drives an increase in intracellular Ca2+, measured using Fluo-4. Cell images show the Fluo-4 fluorescence associated with different time points during the recording. 1 mM ATP was applied as a viability test, and only viable cells were selected for analysis. b, 100 nM TLQP-21 densensitises macrophage to further TLQP-21 stimulation, but not the ATP response. C, 100 nM TLQP-21 causes an increase in intracellular Ca2+ in cultured brain microglia.

(4) FIG. 3A-F gC1qR is the receptor for TLQP-21. a, Biotinylated TLQP-21 was conjugated to Sulfo-EMCS cross-linker, and applied to membrane fractions of 6 weeks old rat brain and spinal cord for cross-linking (boric acid buffer, pH 8, with 150 mM NaCl, 3 hours incubation on ice). The reaction was terminated using 50 mM Tris buffer, and samples were ethanol precipitated and resolved using Tricine-PAGE and visualised by Western blot analysis by streptavidin-horse radish peroxidase. A clear band at ˜30 kDa (indicated by an arrow) was observed following chemical crosslinking using biotinylated TLQP-21., which was many orders of magnitude greater than the corresponding band in the membrane control lane using unconjugated Sulfo-EMCS cross-linker. b, Membrane fractions of P4 rat brain was applied to either monomeric avidin column attached with TLQP-21 or monomeric avidin column only (“Negative control”). Following considerable washes, proteins bound to the columns were eluted and resolved on SDS-PAGE, followed by silver staining. A ˜30 kDa band (arrow) was apparent in the elutant from the TLQP-21-attached column. C, The ˜30 kDa band was analysed by LC-MS/MS Orbitrap following trypsinisation. MS/MS fragmentation spectra show three unique peptides which have sequence identities to gC1qR. d, Transfection of siRNA against gC1qR (siRNA 1-4) into macrophages successfully reduced gC1qR protein expression. Non-specific negative control siRNA and did not alter the gC1qR expression. e, Transfection of siRNA against gC1qR into macrophages caused significant reduction in number of cells responding to TLQP-21. f, Pre-incubation (15 minutes) of macrophages with anti-gC1qR antibodies (MAb1, MAb2, 3 μg/ml each) significantly attenuates the TLQP-21-induced increase in intracellular Ca2+ levels.

(5) FIG. 4 Pre-treatment with the gC1q-R neutralising antibody (15 mins) attenuates the TLQP-21 induced Ca2+ increase in macrophages

(6) FIG. 5 Intraplantar injection of the LQEQ-19 (275 microgram) but not vehicle control was associated with a hypersensitivity to mechanical stimuli which developed in the ipsilateral hind limb, 10 minutes after injection. p≦0.001 vs vehicle ANOVA (Turkey)

(7) FIG. 6A-C Intraplantar injection of macrophages stimulated with TLQP-21 can evoke mechanical hypersensitivity, and anti-gC1qR antibody reverses mechanical hypersensitivity in partial sciatic nerve ligation (PSNL) model. a, 80,000 macrophages treated with 100 nM TLQP-21 (closed circle) and scrambled TLQP-21 (open circle) for 24 hours have been intraplantarly injected into 3 weeks old male rats. Mechanical sensitivity was examined by electrical Von Frey test. Injection of macrophages stimulated with TLQP-21 caused reduction of paw withdrawal thresholds at 24 and 48 hours after injection. Mean±s.e.m. *P<0.05 vs scrambled TLQP-21. b, qRT-PCR revealed significant upregulation of VGF mRNA in DRG of partial sciatic nerve ligation (PSNL) model rats. C, Time course of paw withdrawal thresholds to Von Frey mechanical stimulation on an left hind paw of PSNL model rats. The left sciatic nerve was exposed, tied with non-absorbable silk thread, and wrapped loosely with a oxidized regenerated cellulose previously soaked in 200 μl of PBS (open triangle) or PBS containing 25 μg of anti-gC1qR (closed circle) or control antibodies (open circle). Application of anti-gC1qR antibody significantly attenuated the hypersensitivity caused by PSNL 1 day after the surgery. Mean±s.e.m. *P<0.05 vs controls.

(8) FIG. 7 LQEQ-19 sensitises nociceptors in vitro. (A) Typical average trace of 12 compound action potential recordings. The record was divided into 3 components according to the conduction velocities of Aβ fibres (6.2 m/s-2.1 m/s), Ad fibres (2.1 m/s-0.8 m/s) and C fibres (0.8 m/s-0.1 m/s) fibres. (B) Maximum amplitudes of Aβ, Ad and C components of compound action potentials. (C) Area under the curve of Aβ, Ad and C compound action potential. Bold line on the X axis indicates LQEQ-19 application

(9) FIG. 8: Hind paw injection of TLQP-21-treated macrophage produced tactile allodynia. Macrophages were treated with either 100 nM TLQP-21 or 100 nM scrambled TLQP-21 for 24 hours in culture. Following wash with PBS, macrophages (35,000 cells in 50 μl) were injected into the left hind paw. Ipsilateral paw withdrawal latency to Von Frey mechanical stimulation was measured at 1, 2, and 3 days after injection (n=9).

(10) TABLE-US-00001 SEQ ID NO: 1 Thr-Leu-Gln-Pro-Pro-Ala-Ser-Ser-Arg-Arg-Arg-His- Phe-His-His-Ala-Leu-Pro-Pro-Ala-Arg-His-His-Pro- Asp-Leu-Glu-Ala-Gln-Ala-Arg-Arg-Ala-Gln-Glu-Glu- Ala-Asp-Ala-Glu-Glu-Arg-Arg-Leu-Gln-Glu-Gln-Glu- Glu-Leu-Glu-Asn-Tyr-Ile-Glu-His-Val-Leu-Leu-His- Arg-Pro SEQ ID NO: 2 Leu-Gln-Glu-Gln-Glu-Glu-Leu-Glu-Asn-Tyr-Ile-Glu- His-Val-Leu-Leu-His-Arg-Pro SEQ ID NO: 3 Thr-Leu-Gln-Pro-Pro-Ala-Ser-Ser-Arg-Arg-Arg-His- Phe-His-His-Ala-Leu-Pro-Pro-Ala-Arg

(11) The data generated indicates both mRNA and protein levels of VGF are upregulated in small diameter DRG neurons from rats following varicella zoster (VZV) infection (FIG. 1A) and L5 spinal nerve transection (FIG. 1B) compared to corresponding controls (FIG. 1C,D). This increased VGF-immunoreactivity in injured DRG neurons has been confirmed by other groups, as well as the upregulation of VGF-immunoreactivity in central terminals and their target dorsal horn neurons following nerve damage.sup.19,20.

(12) Our preliminary data showed that 100 nM TLQP-21(SEQ ID NO: 3), but not scrambled TLQP-21, TLQP-62 (SEQ ID NO: 1) nor LQEQ-19 (SEQ ID NO: 2), causes intracellular Ca.sup.2+ increase in cultured macrophage visualised by Fluo-4 (FIG. 2), and this is due to Ca.sup.2+ release from endoplasmic reticulum. The same phenomena were observed in cultured primary microglia.

(13) TLQP-21 caused transient increase in intracellular Ca2+ levels in bone marrow-derived macrophages even at a concentration of 100 nM (FIG. 2A). This increase in intracellular Ca2+ levels elicited by TLQP-21 seems to be due to release of Ca2+ from their intracellular Ca2+ stores such as endoplasmic reticulum (ER) or mitochondria, because the Ca2+ increase is still observed when extracellular Ca2+ is depleted. A scrambled TLQP-21 (ScrTLQP-21) did not induce an increase in intracellular Ca2+ levels in these cells (supplementary figure). Interestingly, 100 nM TLQP-21 treatment induced de-sensitisation to subsequent TLQP-21 treatments, but not to ATP treatments (FIG. 2B). A possible explanation for the absence of a Ca2+ response from a second application of TLQP-21 is that there is a biological de-sensitisation occurring such as phosphorylation of the receptor. It is also possible that this could be due to depletion of Ca2+ in internal stores such as ER, however, this is less likely because the de-sensitisation occurs even with sufficient time (2 hours) to recover and replenish the Ca2+, and ATP treatment gave an increase in intracellular Ca2+ levels. Actually this de-sensitisation by TLQP-21 has also been observed in cerebellar granule cells. These observations suggest that the effect of TLQP-21 on macrophages and microglia cells is a specific biological response, and indicate presence of specific receptor for TLQP-21 in those cells. We also observed that brain microglia responded to TLQP-21 similarly to macrophages (FIG. 2C).

(14) Our PCR array experiments revealed that chemokine Ccl11 is 2.78-fold upregulated in microglia upon TLQP-21 stimulation, whereas another chemokine Cxcl9 is 2.28-fold downregulated. Ccl11 has been linked to inflammation.sup.23, while Cxcl9 is known as a natural antagonist to Ccl11 receptor CCR3.sup.24. We then used Sulfo-EMCS-conjugated TLQP-21 to purify and identify receptor(s) for TLQP-21. Whole brain tissue from post-natal day 4 rats was used, as this was the same tissue used to extract microglia for use in Ca.sup.2+ imaging. The membrane fractions of rat brain was incubated with the crosslinker-conjugated TLQP-21, and analysed by Tricine-PAGE and Western blotting using Streptavidin-HRP for the biotin tag on TLQP-21. A ˜30 kDa band appeared when the conjugated TLQP-21 was applied to the membrane preparation (FIG. 3A), but not in the membrane control (with Sulfo-EMCS crosslinker in the absence of TLQP-21). We also used biotin-tagged TLQP-21 and a monomeric avidin column to purify TLQP-21 binding proteins. The membrane fraction of rat brain was applied to a TLQP-21 attached column, and the elutions were analysed on SDS-PAGE and silver staining for direct comparison to the negative control (without TLQP-21). A ˜30 kDa band (FIG. 3B, arrow) was also apparent with TLQP-21 attached to the column, but not in the corresponding negative control. The ˜30 kDa bands from both gels were cut out, trypsinised and analysed using LC-MS/MS Orbitrap. A same protein was identified in the two distinct experiments with good peptide coverages, the receptor of the globular part of the complement protein C1q, designated gC1q-R. gC1q-R is an ubiquitous multiligand-binding protein involved in multiple cellular functions including inflammation and infection. gC1q-R is highly expressed in microglia and macrophage, and co-purified with TLQP-21. Pre-incubation of macrophage with 3 μg/ml of the neutralising gC1q-R monoclonal antibody for 15 minutes resulted in unresponsiveness to TLQP-21

(15) To identify the receptor for TLQP-21, in addition to chemical cross-linking we employed mass spectrometry. The modified TLQP-21 was used with a biotin covalently attached via the amide bond at the N-terminus, and an extra cysteine residue was included at the C-terminus. Sulfo-EMCS cross-linker was conjugated to the modified TLQP-21 via the sulphydryl group of cysteine at the C-terminus. This cross-linker-conjugated TLQP-21 was able to induce an increase in intracellular Ca2+ levels similar to the wild type TLQP-21 (data not shown).

(16) To elucidate the identity of the ˜30 kDa protein, which were apparent in two different experiments, the protein band from the monomeric avidin experiment was analysed using LC-MS/MS Orbitrap. We identified three unique peptides which have sequence identities to gC1qR (FIG. 3C). The complement-binding protein, gC1qR is a highly acidic ˜30 kDa protein, ubiquitously expressed and binds to the globular heads of C1q, the first subcomponent of the classical pathway for complement activation. It has been observed that gC1qR is a multi-functional protein (Ghebrehiwet and Peerschke, 2004). Western blot analysis confirms that the gC1qR protein appears at ˜30 kDa in the elutions for the column with TLQP-21 attached, but not in the corresponding negative controls. Western blot also shows that macrophage and microglia cells express gC1qR.

(17) (FIG. 4). This proves that gC1q-R is the receptor for TLQP-21, suggesting TLQP-21 acts on microglia and macrophage through gC1q-R and causes hyperactivity of DRG and/or spinal cord neurons.

(18) On the other hand, another VGF-derived peptide LQEQ-19 seems to have a direct role on DRG neurons. Intraplantar injection of LQEQ-19 in rats is associated with a hypersensitivity to mechanical stimuli (FIG. 5), and that application of LQEQ-19 to DRG significantly increases both the amplitude and the area under the curve of the C-fibre component of compound action potentials in dorsal roots (FIG. 6), suggesting that LQEQ-19 may act as an autocrine factor for nociceptive primary sensory neurons. In summary, there are at least three active VGF peptides involved in pain pathways, i.e., TLQP-62, TLQP-21 and LQEQ-19, and four types of cells, namely, spinal microglia, macrophage, nociceptive DRG neurons, and dorsal horn neurons, which respond to these peptides. In this project we will focus on the putative role of VGF peptides in regulating the activity/excitability of DRG neurons and the novel VGF-induced signaling pathway in microglia/macrophage.

(19) Useful data have been obtained concerning the physiological functions of VGF peptides from mice subjected to targeted deletion of the VGF gene.sup.19,25,26.

(20) To Confirm the Cellular Pattern and Time Course of Expression of VGF and Associated Peptides in Primary Sensory Neurons in Models of Peripheral Neuropathic Pain:

(21) We used co-localisation immunohistochemistry to examine the chronology and cellular pattern of VGF expression in DRGs harvested from animal models of neuropathic pain. A number of anti-VGF primary antibodies are now commercially available, and we initially screened them, including the polyclonal antibody that was used in the pilot experiments (FIG. 1), in hypothalamus (as a positive control), spinal cord and DRG from naive rats. We then used the optimal VGF antibody to study DRG and spinal cord expression of VGF in a model of traumatic neuropathy (L5 spinal nerve transection.sup.27,28), VZV-associated pain where rats are inoculated with VZV.sup.11,29,30 and a model of HIV neuropathy where rats are treated with a combination of perineural HIV GP120 and systemic treatment with the antiretroviral drug Zalcitabine.sup.6,10. Animals were behaviourally characterised and only those showing a decrease in baseline hind limb withdrawal threshold to a mechanical stimulus >30% from baseline were used. In tissue taken from VZV infected animals additional co-localisation studies of VGF and the viral protein IE6211 may be performed in order to determine the cellular relationship between VZV infection and VGF immunoreactivity. Furthermore, the expression of VGF in DRGs from L5 spinal nerve transected animals was examined in both L5 and L4 DRGs to determine the relationship of VGF expression to peripheral nerve trauma of both injured and uninjured sciatic neurons.sup.31. To determine the chronology of VGF expression this will be performed at a number of time points after the creation of neuropathy. Experience from previous studies indicate that we require a group size of n=6 for histological studies. We will also perform western blotting and qRT-PCR for quantitative analysis of VGF expression in DRG in these pain model animals.

(22) Analysis the promoter region of VGF gene responsible for activation triggered by nerve damage was performed. Our preliminary experiment identified that the 853 bp upstream sequence of VGF gene possesses functional promoter region. We further characterised the promoter region responsive to nerve damage and inflammation by deletion analysis. A series of VGF promoter-Luciferase constructs containing different length of the VGF promoter region were MicroPorated into cultured DRG neurons. The promoter activity in response to various noxious stimuli such as NGF and gp120 was be studied and the essential promoter element(s) was be identified. We then examined the involvement of the element(s) in VGF expression by introducing site-directed mutations to the element(s). The wild type- and mutant-VGF promoter-Luciferase constructs were then be cloned into replication-defective vectors based on herpes simplex virus (HSV). It has been recently reported that HSV vectors show high transduction efficiency in DRG neurons in vivo.sup.32. We injected the HSV vector containing wild type- and mutant-VGF promoter-Luciferase complex into the tibial nerve of Wister rats (once daily, 5 μl). A GFP expression vector was co-injected to monitor transduction efficiency. The rats were subjected to three neuropathic pain models mentioned above, and the Luciferase activity of each VGF promoter constructs in DRG neurons will be analysed by luminometer after extracting the DRGs from rats.

(23) To Investigate Consequences of VGF siRNA Application in Neuropathic Pain Models:

(24) We searched for the most potent siRNA sequence to downregulate the VGF protein expression in cultured DRG neurons using real-time qRT-PCR and immunocytochemistry as validation methods. According to our experience.sup.33, at least one out of three siRNA sequences efficiently suppressed the target protein expression. Once the siRNA sequence was determined, we observed the in vivo effect of siRNA treatment in all three models of neuropathic pain via intrathecal injection method (VGF-specific siRNA, the scrambled control siRNA, or a vehicle control) as we previously showed successful downregulation of a specific gene expression in DRG in vivo.sup.34. Injections were carried out both at the time of the induction of the neuropathy and once the neuropathy is established (power calculation indicates a group size of n=12). The effect of siRNA on naïve and appropriate sham treated animals for each model was also assessed. The behavioural/sensory threshold experiments were conducted in the same fashion as described in aim 1. We will also assess the animals for anxiety-like behaviour (thigmotaxis).sup.9-11,35.

(25) Transfection of siRNAs against gC1qR into macrophages also significantly reduced the protein levels of gC1qR (FIG. 3D) and the number of cells responding to TLQP-21 (FIG. 3E). Pre-incubation of macrophages for 15 mins with neutralising gC1qR monoclonal antibodies resulted in significant reduction of the response to TLQP-21 (FIG. 3F). These data prove that gC1qR is the receptor for TLQP21.

(26) To Study Efficacy and Potency of VGF Derived Peptides in Nociception:

(27) Currently, 13 VGF-derived peptides have been identified. Although our preliminary data demonstrated that LQEQ-19 sensitises nociceptors in vitro and causes a mechanical hypersensitivity in vivo, and TLQP-21 causes Ca.sup.2+ increase in microglia/macrophage leading to transcriptional regulations of chemokines, there may be other VGF peptides with more potent effect on sensory thresholds. A longer VGF peptide (TLQP-62) induces pain behaviour (cold and mechanical hypersensitivity) when administered intrathecally in nanomolar concentrations.sup.19. TLQP-62 and AQEE-30 were found to increase synaptic activity in the hippocampal neurons.sup.22, while QAEA-38 (also known as NERP-2) is involved in physiological regulation of water homeostasis.sup.36. Furthermore, LQEQ-19 causes P38 MAP kinase phosphorylation in microglia.sup.20 and enhances pain behaviour in the formalin test.sup.17 and also biological activity in other physiological systems.sup.37-39.

(28) In vitro studies: In order to identify the most potent VGF peptide in activating DRG neurons and microglia/macrophage, we will screen up to ten VGF-derived peptides in vitro. These peptides were either commercially sourced or provided by Neusentis/Pfizer. The effects of VGF peptides on sensory neurons was analysed using whole-cell current-clamp recordings on cultured DRG neurons. Responses of cells to depolarising current pulses will be analysed before and after superfusion of peptides and their efficacy and potency established. The nociceptive phenotype of the cells was confirmed by superfusing capsaicin to the cells at the end of the recordings, and analysing the action potential and current threshold of the cells. Based on our pilot data with LQEQ-19, we expected that some of these peptides will increase the activity of nociceptive neurons. The activation of microglia and macrophage was studied on two parameters, intracellular Ca.sup.2+ increase and P38 MAP kinase phosphorylation. Intracellular Ca.sup.2+ levels will be monitored using fluo-4 under a confocal microscope as shown in FIG. 2 and FIG. 4. The phosphorylation levels of P38 MAP kinase was investigated as shown before.sup.20. Once we identified peptides capable of activating sensory neurons and/or microglia/macrophage, confirmed the specific effects using scrambled peptides.

(29) In vivo experiments: Having identified “lead” VGF peptides in vitro (above), we investigated their properties in vivo, using 2 strategies. Acute experiments: Initially, we administered the peptides by intraplantar and intrathecal injection to male Wistar rats and determine the effect of the peptide on mechanical, cold and thermal sensory thresholds for limb withdrawal and spontaneous foot lifting/licking, over two hours.sup.19. Three point dose response curves was constructed and a vehicle control group included. Chronic experiments: Once the optimal peptide and concentration have been determined we will examine the effect of prolonged application of two “lead” VGF peptide to the sciatic nerve and spinal cord of male Wistar rats using an implanted osmotic mini-infusion Alzet pump attached to a perineural and intrathecal catheter for infusion over 14 days.sup.40. We have previously demonstrated the utility of perineural administration in other models of peripheral neuropathic pain.sup.9,10. Again, three doses were administered and there was a vehicle control group, with randomisation and blinding. We monitored hind-limb withdrawal thresholds/latency to static and dynamic mechanical stimuli as well as thermal and cool stimuli.sup.9-11,27 over 28 days and compare these to baseline values. We will also monitored the animals for spontaneous foot lifting/licking and anxiety-like behaviour (thigmotaxis) in the open field paradigm at day 14.sup.9-11,35. At the end of these experiments (28 days) and smaller cohorts (7 and 14 days) the animals were culled, perfused fixed and the DRGs and spinal cord harvested for the immunohistochemical studies detailed below.

(30) We hypothesised that macrophages stimulated by TLQP-21 affects sensory neurons and alter the mechanical sensitivity. We tested this hypothesis by measuring paw withdrawal thresholds in normal rats after hind paw injection of cultured macrophages that had been pre-treated with either TLQP-21 or ScrTLQP-21 for 24 hours. ScrTLQP-21 treated macrophages injection did not affect the paw withdrawal threshold. In contrast, the paw withdrawal threshold decreased markedly 24 hours after the injection of macrophages stimulated by TLQP-21 (FIG. 6). This effect lasted for 48 hours after injection. We then examined if VGF mRNA is upregulated in DRG of partial sciatic nerve ligation (PSNL) model rats. qRT-PCR revealed that VGF mRNA is significantly upregulated in our PSNL model (FIG. 3b). This data strongly support the previous observations VGF is a commonly upregulated molecule in chronic pain models. We then examined if in vivo application of the neutralising gC1qR antibody can prevent or delay development of neuropathic pain in PSNL model rats. The gC1qR antibody was applied to the site next to nerve ligation, in a cellulose membrane soaked form. After 24 hours of PSNL, vehicle and control IgG treated rats showed dramatic reduction of mechanical threshold measured by Von Frey mechanical stimulation. In contrast, application of the gC1qR antibody substantially attenuated the hypersensitivity caused by PSNL. These results suggest that macrophages stimulated by TLQP-21 via its receptor gC1qR cause hyper-excitation of sensory neurons.

(31) As its name suggests, gC1qR was originally identified as a protein with high affinity for the globular heads of the complement component C1q. It is, however, now known to be able to interact with a large variety of ligands. gC1qR is a 33 kDa, highly acidic, and ubiquitously expressed protein. It has a doughnut-shaped trimer structure, and can form a disulfide bond between monomers of different gC1qR trimers, resulting in a hexameric structure (Jiang et al. 1999). It was observed that fibroblasts expressing gC1qR, after application of the complement C1q protein, induced a rapid and transient increase in intracellular Ca2+ levels via an IP3-dependent pathway (Bordin et al. 1998). It has been observed that gC1qR can bind both high molecular weight kininogen (HK) and factor XII, and more recently it was observed that the HK-gC1qR interaction plays an important role in bradykinin generation in macrophages (Barbasz et al. 2008). Thus, the gC1qR protein, particularly when on the cell surface, can bind plasma proteins such as C1q and HK, which in turn generates an inflammatory response from both the complement and kinin/kallikrein systems and initiates a plethora of biological responses. Macrophages secrete diverse signaling molecules such as cytokines, chemokines, and growth factors, which can sensitise sensory neurons. It would be interesting to see if any particular cytokines are dysregulated in macrophages upon TLQP-21 stimulation, and such cytokines may have direct effects on hypersensitivity of sensory neurons. It is also important to study how TLQP-21-mediated activation of microglia relates to P2X-mediated mechanical allodynia.

(32) Although roles of macrophages in inflammatory pain have been well documented, involvement of macrophages in neuropathic pain signaling has not been studied in detail. There is firm evidence that resident macrophages in DRG proliferate after nerve injury (Mueller et al. 2001), and circulating monocytes are recruited into the site of injury (Abbadie et al. 2003). Systemic depletion of macrophages reduces mechanical hypersensitivity after peripheral nerve injury (Liu et al. 2000). It has also been shown that depletion of macrophages delays progression of neuropathic pain in diabetic model rats (Mert et al. 2009).

(33) The present data suggest that disrupting TLQP-21-gC1qR interaction and/or its downstream signaling may provide a new way of controlling chronic pain.

(34) To Identify the Mechanisms Involved in the VGF-Evoked Activation of Primary Sensory Neurons, Spinal Microglia and Macrophage:

(35) Previous data indicate that VGF-derived peptides activate various intracellular signaling molecules, including the extracellular signal-regulated kinase 1/2 (ERK1/2) and protein kinase B (PKB/Akt) in neurons.sup.39. ERK1/2 and PKB/Akt have been shown to modify the activity of membrane molecules in neurons including the delayed rectifier K.sup.+ channel and the noxious heat transducer TRPV1, which result in increased activity of the cells.sup.41-43. It is also reported that there is an increase of phosphorylated p38 MAP kinase in spinal microglia of mice injected intrathecally with LQEQ-19.sup.20. Here, we studied the activation of primary sensory neurons by recording whole-cell currents and identifying the membrane and intracellular signaling molecules involved in the VGF-derived peptide-induced increase in the activity of DRG neurons. Initial assessment of voltage-gated channels affected by VGF-derived peptide(s) was performed by activating the channels by a simple voltage protocol. Depending on the results of the initial assessment, the effect of VGF-derived peptide(s) will be studied on Na.sup.+, K.sup.+ and Ca.sup.2+ currents isolated by ionic substitution, biophysical methods and/or pharmacology. The nociceptive phenotype of the cells was confirmed by applying capsaicin at the end of the recordings. In DRGs from VGF peptide-treated animals (aim 3, chronic experiments) we will perform immunohistochemistry for markers known to be dysregulated in neuropathy including markers of neuronal stress and regeneration, apoptosis and drug targets (e.g. ATF3, GAP43, caspase-3, c-Jun, galanin, neuropeptide Y, selected Na.sup.+ channels, α.sub.2δ.sub.1 Ca.sup.2+ channel subunits). To determine the phenotype of cells expressing these markers we performed a cell size analysis combined with co-localisation studies using established markers of DRG cell phenotype (e.g. NeuN, peripherin, NF-200, TRPV1, IB4, CGRP and non-neuronal cells GFAP and lba-1) using antibodies we have successfully used in previous studies.sup.9,10,44,45.

(36) Two transducer molecules, TRPV1 and the cold-sensitive TRPA1 have been implicated.sup.46,47 in the development of nerve injury-associated pain. Therefore, here we also assessed the effect of VGF-derived peptide(s) on the excitability of TRPV1 and TRPA1 using whole-cell voltage-clamp recordings from cultured primary sensory neurons and by activating these receptors by their specific and selective activators, capsaicin (100 nM) and cinnamaldehyde (100 μM), respectively. Studies on signaling molecules involved in VGF peptide-induced changes will involve measuring the activity of membrane molecules which are affected by the peptide(s). Here, MEK (e.g. PD 98059), phosphatidylinositol 3-kinase (e.g. LY294002), and p38 MAPK (e.g. SB202190) inhibitors will be used to elucidate whether PKB/Akt, ERK1/2, and/or p38 MAPK are involved in the effect. The VGF peptides identified in Aim 1 was be applied at 75% of the EC50 determined during the current-clamp recordings for 1 minute in all experiments.

(37) Our preliminary data shows TLQP-21 increases Ca.sup.2+ release from endoplasmic reticulum in microglia and macrophage (FIG. 2). We investigated the involvement of IP3 and characterisation of phospholipase C (PLC) which is responsible for the IP3 production in microglia/macrophage upon TLQP-21 stimulation using siRNA specific to isozymes of PLC. Once the PLC involved in TLQP-21-evoked Ca.sup.2+ release was identified, we further investigated the upstream signaling mechanism of the PLC. From this angle, we were able to narrow down the candidate receptors for TLQP-21. The downstream signaling of the Ca.sup.2+ release was studied by analysing expression levels of multiple markers for microglia/macrophage activation such as P2X4, P2X7, P2Y6, Kv1.3, BDNF and chemokines by qRT-PCR. In a similar way, we also investigated the p38 MAP kinase cascade in microglia in response to LQEQ-19 stimulation. We also used a DNA microarray to investigate differences in mRNA expression between TLQP-21 and scrambled TLQP-21 stimulated microglia and macrophage (n=4 at four different time points). The authenticity of gC1q-R as a TLQP-21 receptor was further investigated by gC1q-R siRNA electroporation into cultured microglia and macrophage. 1. Scott F. T. et al J Med Virol 2003; 70 Suppl 1:S24-S30. 2. Gauthiera A. et al Epidemiology and Infection 2009; 137(01):38-47. 3. Smyth K. et al HIV Med 2007; 8:367-373. 4. Hempenstall K. et al Public Library of Science-Medicine 2005; 2:628-644. 5. Finnerup N. B. et al Pain 2005; 118:289-305. 6. Maratou K. et al European Journal of Pain 2009; 13(4):387-398. 7. Costigan M. et al BMC Neuroscience 2002; 3:16. 8. Xiao H. S. et al Proceedings of the National Academy of Sciences 2002; 99:8360-8365. 9. Wallace V. C. J. et al Pain 2007; 133:47-63. 10. Wallace V. C. J. et al Brain 2007; 130:2688-2702. 11. Hasnie F. S. et al Neuroscience 2007; 144:1495-1508. 12. Levi A. et al Science 1985; 229:393-395. 13. Salton S. R. et al Front Neuroendocrinol 2000; 21:199-219. 14. Levi A. et al Cellular and Molecular Neurobiology 2004; 24:517-533. 15. Eagleson K. L. et al J Neurosci 2001; 21:9315-9324. 16. Snyder S. E. et al Brain Res Mol Brain Res 1997; 49:307-311. 17. Rizzi R. et al Neuroscience Letters 2008; 441:129-133. 18. Ferri G. L. et al Brain Res Mol Brain Res 1992; 13:139-143. 19. Moss A. et al Molecular Pain 2008; 4:62. 20. Riedl M. S, et al J Neurosci 2009; 29(42):13377-13388. 21. Possenti R. et al EMBO J 1989; 8:2217-2223. 22. Alder J. et al J Neurosci 2003; 23:10800-10808. 23. Waddell A. et al J Immunol 2011; 186(10):5993-6003. 24. Loetscher P. et al J Biol Chem 2001; 276: 2986-2991. 25. Hahm S. et al Neuron 1999; 23:537-548. 26. Watson E. et al Endocrinology 2005; 146:5151-5163. 27. Bridges D. et al Br J Pharmacol 2001; 133:586-594. 28. Kim S. H., Chung J. M. Pain 1992; 50:355-363. 29. Fleetwood-Walker S. M. et al J Gen Virol 1999; 80:2433-2436. 30. Garry E. M. et al Pain 2005; 118:97-111. 31. Hudson L. J. et al Eur J Neurosci 2001; 13:2105-2114. 32. Anesti A. M, et al Nucleic Acids Res 2008; 36(14):e86. 33. Shao D. et al Mol Cell Neurosci 2009; 42(3):219-225. 34. Baker M. D. et al Mol Cell Neurosci 2011; 48(3):258-265. 35. Wallace V. C. J. et al Br J Pharmacol 2007; 151:1117-1128. 36. Toshinai K, Nakazato M. Cell Mol Life Sci 2009; 66(11-12):1939-1945. 37. Bartolomucci A. et al Proc Natl Acad Sci USA 2006; 103:14584-14589. 38. Jethwa P. H. et al Endocrinology 2007; 148:4044-4055. 39. Severini C. et al J Neurochem 2008; 104:534-544. 40. Lever I. J. et al Br J Pharmacol 2007; 151:292-302. 41. Zhu W., Oxford G. S. Mol Cell Neurosci 2007; 34:689-700. 42. Zhuang Z. Y. et al J Neurosci 2004; 24:8300-8309. 43. Kayssi A. et al J Physiol 2007; 580:977-991. 44. Bridges D. et al Neuroscience 2003; 119:803-812. 45. Farquhar-Smith W. P. et al Mol Cell Neurosci 2000; 15:510-521. 46. Obata K. et al J Clin Invest 2005; 115(9):2393-2401. 47. Christoph T. et al Neurochem Int 2007; 50(1):281-290.